CALR mutations occur in about 20% of patients with primary and post-essential thrombocythemia myelofibrosis, as per the study. Regardless of driver mutations, patients with splenomegaly and symptoms ...

JAK2 V617F mutation: A recurrent somatic point mutation in the Janus kinase 2 gene that leads to constitutive activation of proliferative signalling pathways in myeloproliferative neoplasms.

Essential thrombocythemia (ET) is a type of rare blood disorder that causes an increase in the number of blood cells. Read more.

“A subset of patients with MPN-U showing early-stage disease, thrombosis, and JAK2 mutation may warrant recognition based on very favorable prognosis, with treatment focused on management of ...

A rare case report describes a young woman whose relapse of AML following MPN coincided with severe worsening of pulmonary hypertension, highlighting the need for vigilant cardiopulmonary monitoring ...

How do you think about it, if at all, differently in the context of the driver mutations, JAK2 vs MPL vs [calreticulin]? What is your interpretation of the data, mostly focusing on JAK2 here?

Approximately 90% of patients diagnosed with myelofibrosis have JAK2, CALR or MPL driver mutations, according to study background. In addition, 10% to 30% of individuals relapse following HSCT.

A groundbreaking study has uncovered how specific genetic mutations influence cancer treatment outcomes -- insights that could help doctors tailor treatments more effectively. The largest study of ...